Your browser doesn't support javascript.
loading
Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.
Corso, A; Mangiacavalli, S; Barbarano, L; Montalbetti, L; Mazzone, A; Fava, S; Varettoni, M; Zappasodi, P; Morra, E; Lazzarino, M.
Afiliación
  • Corso A; Division of Hematology, IRRCS Fondazione Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy. a.corso@smatteo.pv.it
Leuk Res ; 32(7): 1085-90, 2008 Jul.
Article en En | MEDLINE | ID: mdl-18096226
Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Mieloma Múltiple / Antineoplásicos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Año: 2008 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Mieloma Múltiple / Antineoplásicos Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Año: 2008 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido